[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335595-105":59,"doc-detail-335595-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-chemoprotective-effect-of-anti-platelet-agents-on-cancer-incidence-in-people-with-non-alcoholic-fatty-liver-disease-nafld-retrospective-cohort-study","The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD) - retrospective cohort study","","Non-alcoholic fatty liver disease (NAFLD) is linked to higher hepatic and extrahepatic cancer incidence, especially cancers associated with obesity. Using anonymised electronic medical records from the TriNetX network, a retrospective cohort study assessed whether aspirin or other antiplatelet agents reduce cancer outcomes in adults diagnosed with NAFLD before antiplatelet initiation. Propensity score matching compared antiplatelet users with non-users, with follow-up for five years and subgroup and sensitivity analyses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-chemoprotective-effect-of-anti-platelet-agents-on-cancer-incidence-in-people-with-non-alcoholic-fatty-liver-disease-nafld-retrospective-cohort-study/335595/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-chemoprotective-effect-of-anti-platelet-agents-on-cancer-incidence-in-people-with-non-alcoholic-fatty-liver-disease-nafld-retrospective-cohort-study/335595.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study purpose regarding antiplatelet agents and NAFLD?","Question",{"text":112,"@type":113},"To explore whether aspirin or other antiplatelet agents have a chemoprotective effect against obesity-related cancers, including hepatocellular carcinoma, in people with NAFLD.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants selected and groups compared?",{"text":117,"@type":113},"Adults aged 18+ diagnosed with NAFLD before starting antiplatelet agents were identified, then compared as antiplatelet use versus no antiplatelet use, with propensity score matching for nine variables.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes and follow-up period were assessed?",{"text":121,"@type":113},"The main outcomes were incidence of hepatocellular carcinoma and other obesity-related cancers, with follow-up for five years, including subgroup analyses among aspirin users and sensitivity analyses for different exposure durations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335595,1790014575,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Anson etal. BMC Medicine (2024) 22:574 [https://doi.org/10.1186/s12916-024-03802-4](https://doi.org/10.1186/s12916-024-03802-4)  \nBMC Medicine  \n RESEARCH Open Access  \nThe chemoprotective effect of anti-platelet   agents on cancer incidence in people  \nwith non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study  \nMatthew Anson1,2,3, Jun Shang Poon3, Alex E. Henney 1,2,3, David Riley1,2,3, Gema H. Ibarbaru4, Cyril Sieberhagen3, Daniel J. Cuthbertson 1,2,3, Uazman Alam1,2,3 and Theresa Hydes 1,2,3*  \nAbstract  \nBackground Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of hepatic and extrahepatic cancers, in particular those linked to obesity. In people with chronic liver disease, aspirin may confer protection against hepatocellular carcinoma (HCC) . We explore the potential chemoprotective effect of aspirin/other antiplatelet agents on obesity-related cancers, including HCC in people with NAFLD.  \nMethods We performed a retrospective cohort study of anonymised electronic medical records using the TriNetX network (Cambridge, MA, USA), a global federated database. We identified adults aged 18 or over with a diagnosis of NAFLD, prior to commencing antiplatelet agents. Two groups were created: antiplatelet (1) versus no antiplatelet use (2) . We propensity score matched for nine variables. Antiplatelet use was defined as aspirin, ticagrelor, cangrelor, clopidogrel or prasugrel use for at least 1 year. The outcomes of interest were incidence of HCC and other obesityrelated cancers. Follow-up was for 5 years. We performed subgroup analyses on aspirin users only and stratified findings for sex and age. Sensitivity analysis was conducted on individuals with 3-and 5-year aspirin exposure.  \nResults Post matching, there were 42,192 people per group. Antiplatelet use in people with NAFLD was associated with statistically significant reduction in all obesity-related cancers (HR 0 . 71, 95% CI 0 .65–0. 78, p \u003C 0. 001) and individually for HCC (HR 0 . 52, 95% CI 0.40–0. 68, p \u003C 0. 001), breast carcinoma (HR 0 . 78, 95% CI 0.66–0. 92, p = 0 . 003), pancreatic carcinoma (HR 0 . 61, 95% CI 0 .47–0. 78, p \u003C 0. 001) and colorectal carcinoma (HR 0 . 68, 95% CI 0 .56–0. 84, p \u003C 0. 001) . For women, there was a significant reduction in risk of ovarian carcinoma (HR 0 . 75, 95% CI 0 .57–0. 98, p = 0 . 034) .  \nAspirin monotherapy was similarly associated with reduced incidence of HCC (HR 0 .46, 95% CI 0 .32–0. 64, p \u003C 0. 001) and all obesity-related cancers (HR 0 . 71, 95% CI, 0 .56–0. 90, p = 0 . 004), with benefits observed in males (HR 0 . 71, 95% CI 0.56–0. 90, p = 0 . 004), females (HR 0 . 77, 95% CI 0 .67–0. 88, p \u003C 0. 001) and in older (HR 0 . 72, 95% CI 0 .63–0. 82, p \u003C 0. 001) but not younger people (HR 0 . 78, 95% CI 0 .60–1. 03, p = 0 . 589) .  \nConclusions Aspirin/antiplatelet agents may have a role in primary cancer prevention in people living with NAFLD. Keywords Hepatocellular carcinoma, Non-alcoholic fatty liver disease, Aspirin, Anti-platelets, Obesity  \n*Correspondence:  \nTheresa Hydes  \n[theresa.hydes@liverpool.ac.uk](theresa.hydes@liverpool.ac.uk)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the","cbCaifUvbHDczTbh","https://ap.wps.com/l/cbCaifUvbHDczTbh","pdf",1516253,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Obesity and cancer risk\n## NAFLD epidemiology and mechanisms","[{\"question\":\"What was the study purpose regarding antiplatelet agents and NAFLD?\",\"answer\":\"To explore whether aspirin or other antiplatelet agents have a chemoprotective effect against obesity-related cancers, including hepatocellular carcinoma, in people with NAFLD.\"},{\"question\":\"How were participants selected and groups compared?\",\"answer\":\"Adults aged 18+ diagnosed with NAFLD before starting antiplatelet agents were identified, then compared as antiplatelet use versus no antiplatelet use, with propensity score matching for nine variables.\"},{\"question\":\"What outcomes and follow-up period were assessed?\",\"answer\":\"The main outcomes were incidence of hepatocellular carcinoma and other obesity-related cancers, with follow-up for five years, including subgroup analyses among aspirin users and sensitivity analyses for different exposure durations.\"}]","The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD) - retrospective cohort study | PDF",1790011556]